Related coverage linked through entity extraction aliases.
May 29, 2026
At ASCO 2026, Rutgers and Ohio State researchers present new breast cancer combination data, lymphoma survival analyses, and a drug donation program that cut medication wait times to about six days.
Jul 11, 2026
MassBio's Align Summit 2026 returns October 15 in Boston with 50+ startups and AI drug discovery tracks. The SITC EU summit adds a pre-clinical models panel, and UCLA's Cell-Cell Symposium 2026 tackles single-cell spatial data challenges.
Aug 06, 2026
Ivermectin is being promoted again for unproven uses like cancer and hantavirus, while several states consider making it available over the counter. Experts stress there is no clinical evidence for these uses and warn of serious side effects. Prescriptions among cancer patients have more than doubled.
Jun 28, 2026
FDA granted early access to a pancreatic cancer drug; final ARROW data for pralsetinib in RET+ NSCLC were published. A Sarah Cannon Research Institute official outlined a tissue-agnostic vision and highlighted new oncology research.
Jul 24, 2026
A sustained telehealth program combining counseling and nicotine replacement therapy boosted 6-month smoking abstinence to 28.4% vs. 14.7% with quitline referral, a national trial found. The intervention was well-engaged and satisfied patients.
Jul 21, 2026
UNM Comprehensive Cancer Center installs MRI-LINAC, enabling real-time tumor tracking and adaptive radiation therapy. The system has treated 10 patients and improves precision, reducing damage to healthy tissue.
Jul 13, 2026
A clinical trial showed that digital symptom check-ins improved quality of life for advanced cancer patients, especially underserved groups. Researchers are also advancing survivorship care and investigating ageing biology to improve recovery in older patients.
Jun 12, 2026
Personalized mRNA vaccines showed promise in pancreatic cancer trials with 7 of 16 patients in remission after five years. Stage 2 melanoma patients saw a 50% decreased death risk with personalized mRNA vaccines. U.S. funding cuts and policy shifts have stalled domestic mRNA cancer research while companies move trials abroad.
Jun 02, 2026
Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.
Apr 25, 2026
A new U.S. clinical study will test whether provider-mediated communication of colorectal cancer genetic risk increases family genetic testing. The trial plans to enroll around 4,000 patients and relatives.
Apr 22, 2026
mRNA cancer vaccines showed promising pancreatic cancer trial results and boosted tumor-fighting drugs in other research. U.S. officials canceled $500 million in vaccine funding, while the NCI is backing a $200 million cancer vaccine partnership.
Apr 15, 2026
PDS Biotechnology announced positive interim Phase 2 Stage 1 data for PDS01ADC plus HAIP in MSS/pMMR colorectal liver metastases. The trial showed a 77.8% objective response rate and about 85% 24-month survival in 9 patients.
Apr 15, 2026
A study published in The Journal of Clinical Investigation found that CXCL11 may help drive endocrine resistance in some hormone receptor-positive breast cancers. Researchers said ED-resistant tumors had increased immune signaling and may be more responsive to immunotherapies.
Mar 31, 2026
Ataraxis AI has launched Ataraxis Breast CTX, an AI test that predicts individualized chemotherapy benefit for breast cancer patients. The tool uses digital pathology and clinical data to estimate patient-level outcomes with and without chemotherapy, moving beyond population averages. The test has been validated across studies involving over 10,000 patients and is now available through CLIA-certified laboratories.
Mar 30, 2026
A secondary analysis of the Southwest Oncology Group S1609 trial found that larger baseline tumor burden correlated with shorter overall survival but not progression-free survival in rare cancer patients treated with nivolumab plus ipilimumab. The study of 722 patients showed tumor burden was independently associated with survival outcomes but not predictive of tumor regression after dual immunotherapy.
Mar 29, 2026
The phase 3 ENVISION trial shows 80% complete response rate for novel bladder cancer chemoablative therapy. AI integration accelerates precision oncology through biomarker identification and targeted treatments. OncoPRO real-time symptom monitoring system enhances patient safety and clinical trial data capture.
Mar 22, 2026
Meta-analysis of seven phase 2 trials shows metastasis-directed therapy plus standard care significantly improves progression-free survival and other endpoints in oligometastatic prostate cancer patients, with a near-significant trend toward improved overall survival.
Mar 20, 2026
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
Mar 18, 2026
Research communities in the US and UK face funding disruptions as governments demand greater alignment with national priorities. UKRI has paused grant programs while early-career researchers advocate for increased NIH funding.
Mar 13, 2026
NIH funded dramatically fewer research grants in 2025, with funding rates dropping from 27% to 20% for established investigators and from 26% to 19% for early-career researchers, according to newly released agency data.
